{"id":76256,"date":"2023-10-24T11:35:34","date_gmt":"2023-10-24T15:35:34","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/cymabay-shares-rise-7-after-revised-breakthrough-therapy-designation\/"},"modified":"2023-10-24T11:35:37","modified_gmt":"2023-10-24T15:35:37","slug":"cymabay-shares-rise-7-after-revised-breakthrough-therapy-designation","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=76256","title":{"rendered":"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation"},"content":{"rendered":"<div id=\"js-article__body\" itemprop=\"articleBody\" data-sbid=\"MW-BT-CO-20231023-705506\" role=\"document\">\n<p>By Chris Wack<\/p>\n<pre><\/pre>\n<p>CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect treatment of primary biliary cholangitis, including pruritus, in adults without cirrhosis or with compensated cirrhosis.<\/p>\n<div class=\"paywall\">\n<p>The stock hit a 52-week high of $18.20 on Sept. 12, and is up 338% in the past 12 months.<\/p>\n<p>The biopharmaceutical company said seladelpar is the only potent, selective, orally active delpar, with phase 3 results demonstrating a statistically significant improvement in PBC-related cholestatic pruritus.<\/p>\n<p>Breakthrough Therapy Designation is granted by the FDA to investigational agents intended to treat a serious or life-threatening disease or condition, and whose preliminary clinical evidence may demonstrate substantial improvement on at least one clinically significant endpoint over available therapy.<\/p>\n<p>The FDA&#8217;s original Breakthrough Therapy Designation for seladelpar was granted in 2019 and was based on preliminary results from a Phase 2 clinical trial. That trial showed that seladelpar was associated with a substantial reduction in serum alkaline phosphatase.<\/p>\n<pre><\/pre>\n<p>Write to Chris Wack at chris.wack@wsj.com<\/p>\n<pre><\/pre>\n<\/p><\/div>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.marketwatch.com\/story\/cymabay-shares-rise-7-after-revised-breakthrough-therapy-designation-4edf15c1?mod=investing\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect treatment of primary biliary cholangitis, including pruritus, in adults without cirrhosis or with compensated cirrhosis. The stock hit a 52-week high [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-76256","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation | iFintechWorld<\/title>\n<meta name=\"description\" content=\"By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=76256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=76256\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-24T15:35:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-24T15:35:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=76256#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=76256\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation\",\"datePublished\":\"2023-10-24T15:35:34+00:00\",\"dateModified\":\"2023-10-24T15:35:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=76256\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=76256#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=76256\",\"url\":\"https:\/\/ifintechworld.com\/?p=76256\",\"name\":\"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-10-24T15:35:34+00:00\",\"dateModified\":\"2023-10-24T15:35:37+00:00\",\"description\":\"By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=76256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=76256\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=76256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation | iFintechWorld","description":"By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=76256","og_locale":"en_US","og_type":"article","og_title":"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation | iFintechWorld","og_description":"By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally","og_url":"https:\/\/ifintechworld.com\/?p=76256","og_site_name":"iFintechWorld","article_published_time":"2023-10-24T15:35:34+00:00","article_modified_time":"2023-10-24T15:35:37+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=76256#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=76256"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation","datePublished":"2023-10-24T15:35:34+00:00","dateModified":"2023-10-24T15:35:37+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=76256"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=76256#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=76256","url":"https:\/\/ifintechworld.com\/?p=76256","name":"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-10-24T15:35:34+00:00","dateModified":"2023-10-24T15:35:37+00:00","description":"By Chris Wack CymaBay Therapeutics shares were up 7% to $14.53 on Monday after the company said the Food and Drug Administration revised the originally","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=76256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=76256"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=76256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/76256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76256"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/76256\/revisions"}],"predecessor-version":[{"id":76257,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/76256\/revisions\/76257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/1898"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}